© Reuters. FILE PHOTO: A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. REUTERS/Yves Herman/File Photo
(Reuters) – Catalent (NYSE:) Inc reported a 17% fall in quarterly revenue on Tuesday, hurt by persistent production-related challenges at the contract drug manufacturer’s major facilities.
The company also said it was delaying its annual report.
Read the full article here
